Abstract-Homocysteine is a risk factor for coronary artery disease (CAD). Folic acid lowers homocysteine and may improve endothelial function in CAD, although the mechanism is unclear. We investigated the effect of folic acid on endothelial function, homocysteine, and oxidative stress in patients with CAD. We also examined the acute effect of 5-methyltetrahydrofolate (5-MTHF), the principal circulating folate, on endothelial function in vivo and on intracellular superoxide in cultured endothelial cells. A randomized crossover study of folic acid (5 mg daily) for 6 weeks was undertaken in 52 patients with CAD. Ten further patients were given intra-arterial 5-MTHF. Endothelial function was assessed by flow-mediated dilatation (FMD). Folic acid increased plasma folate (PϽ0.001), lowered homocysteine by 19% (PϽ0.001), and improved FMD (PϽ0.001). FMD improvement did not correlate with homocysteine reduction. Malondialdehyde and total plasma antioxidant capacity, markers of oxidative stress, were unchanged. 5-MTHF acutely improved FMD (PϽ0.001) without altering homocysteine (Pϭ0.47). In vitro, 5-MTHF abolished homocysteineinduced intracellular superoxide increase (PϽ0.001); this effect was also observed with folic acid and tetrahydrobiopterin. Our data support the beneficial effect of folic acid on endothelial function in CAD but suggest that the mechanism is independent of homocysteine. Reduction of intracellular endothelial superoxide may have contributed to the effect.
levated total plasma homocysteine (tHcy) is associated with an increased risk of cardiovascular disease and appears to be largely independent of other conventional risk factors. 1 However, whether the increased risk is mediated directly by homocysteine or whether it may simply be a marker remains controversial. 2 The metabolism of folate and homocysteine are interrelated, and increasing folate intake augments remethylation of homocysteine, leading to a reduction of up to 25% in its plasma concentration. 3 This effect occurs despite normal plasma folate and can be achieved by folic acid in doses of 400 g to 5 mg/d. 3, 4 This has led to the proposal that folic acid treatment may reduce cardiovascular risk by reducing tHcy.
In homocystinuria, a rare inborn error with markedly elevated tHcy concentrations (Ͼ100 mol/L), folic acid and pyridoxine (vitamin B 6 ) lower tHcy and reduce cardiovascular events, the major cause of mortality. 5 This benefit is observed despite residual tHcy concentrations that are often above the upper limit of "normal," which suggests a benefit from B group vitamins that is independent of homocysteine. 6 However, in the general population, in which tHcy concentrations are much lower (5 to 15 mol/L), 7 there are, as yet, only limited data on the effect of folic acid treatment on cardiovascular outcome. 8, 9 Endothelial dysfunction is a key process in atherosclerosis 10 and has been reported in chronic mild fasting hyperhomocysteinemia in subjects free of vascular disease 11 and in experimental hyperhomocysteinemia, which is induced by methionine loading in normal subjects. 12 Precisely how homocysteine may promote endothelial dysfunction is unclear; however, generation of reactive oxygen species is proposed to be an important mechanism. 13 Recent studies suggest that B group vitamins enhance endothelial function in coronary artery disease (CAD) or hyperhomocysteinemia. However, the data are limited, and the mechanism underlying this improvement has not been established. 14 -17 5-Methyltetrahydrofolate (5-MTHF), the main circulating folate, can improve endothelial function in subjects with hypercholesterolemia who are free of vascular disease and not receiving lipid-lowering treatment. 18 However, the effect of 5-MTHF in subjects with severe CAD on lipid-lowering treatment is unknown.
We sought to determine whether high-dose folic acid supplementation can improve endothelial dysfunction, a surrogate of cardiovascular risk, in patients with significant CAD on standard therapy, and we endeavored to correlate this effect, if any, with changes in plasma homocysteine, plasma folate, and oxidant stress. To further investigate mechanisms, we examined the acute effect of 5-MTHF on endothelial function in a similar group of 10 patients and its effect on intracellular levels of superoxide in cultured porcine aortic endothelial (PAE) cells.
Methods

Subjects
Patients with CAD aged Ͻ70 years were recruited. We defined CAD as either angiographically proven coronary disease (Ն50% luminal stenosis) or a history of myocardial infarction (creatinine kinase rise Ͼ2-fold normal with ECG changes). Plasma homocysteine was not an entry criterion, and levels were not made known to the investigators during the course of the study. Patients were excluded if an acute coronary event had occurred Ͻ3 months before entry or if there was diabetes mellitus, uncontrolled hypertension, fasting plasma cholesterol Ͼ6.5 mmol/L, impaired renal function (creatinine Ͼ120 mol/L), or clinically significant heart failure. Patients actively smoking or who had recently ceased smoking (Ͻ6 months), patients taking antioxidant vitamins (E or C), folic acid, or fish oils, and women on hormone replacement were also excluded.
The present study was designed to recruit a minimum of 46 subjects, to achieve 80% power to detect an improvement in flow-mediated dilatation (FMD) from 40 m on placebo to 80 m on folic acid at the ␣ϭ0.05 level. Of 534 patients screened, 52 were eligible for entry to the folic acid study, and 10 similar subjects were identified for the intra-arterial study. All selected subjects were tested to exclude vitamin B 12 deficiency, which precludes folic acid treatment, before entry.
Study Design
Folic Acid Study
The study was a randomized, double-blind, placebo-controlled crossover design. It involved two 6-week treatment periods of folic acid (5 mg daily) or matched placebo separated by a washout period of 4 months.
Intra-Arterial 5-MTHF Study
The study was open label and investigated the acute effects of 5-MTHF on brachial artery FMD and its NO component.
All patients gave written informed consent, and both protocols were approved by the Local Research Ethics Committee.
Study Protocol
Folic Acid Study
Each patient was studied at week 0, week 6, week 22, and week 28. At each visit, venous blood was collected into Vacutainers. Lipids, glucose, and creatinine were analyzed on the day of sampling; other samples were separated; and the serum/plasma was stored at Ϫ70°C until analysis. Vascular studies were performed by a single experienced operator in a temperature-controlled room (21°C to 24°C) at the same time of day on patients fasted overnight. Medications were omitted on the morning of the visit, and nitrates were withheld for 24 hours before the studies. At each visit, FMD was measured. Vascular measurements were made at baseline, at 1-minute intervals for 6 minutes, and at 8 and 10 minutes after cuff release to establish the time course of vessel diameter change. The nitroglycerin (NTG) response was then recorded.
Intra-Arterial 5-MTHF Study
After baseline venous blood sampling, baseline vascular measurements and the NTG response were recorded, and a period of at least 45 minutes was allowed to elapse. A 27-gauge needle was then inserted into the brachial artery of the nondominant arm. Normal saline was infused at 0.5 mL/min, and this infusion rate was kept constant throughout. The brachial artery was imaged 7-to 10-cm distal to the puncture site, and FMD was measured. After this, 5-MTHF (Sigma Chemical Co) was then infused at 50 g/min to achieve a plasma concentration of at least 457 g/L (1 mol/L), which has been shown to improve endothelial function in untreated hypercholesterolemia. 18 After 30 minutes of infusion, venous blood samples were drawn from the ipsilateral antecubital vein, and FMD was reassessed. N G -Monomethyl-L-arginine (L-NMMA), an inhibitor of endothelial NO synthase (eNOS), was then coinfused (3 mg/min) with 5-MTHF to assess the NO component of the observed FMD. The L-NMMA infusion was then stopped, and during infusion with 5-MTHF, the response to NTG was reassessed.
Noninvasive Measurement of Endothelial Function
FMD was measured by using high-resolution ultrasound and wall tracking, as previously described by us 19 in response to increased flow in the brachial artery induced by release of a cuff placed at the wrist inflated for 5 minutes at 250 mm Hg. FMD was taken as the greatest absolute increase in vessel end-diastolic diameter (EDD) during the first 3 minutes after cuff release. Endotheliumindependent dilatation in response to NTG (400 g) was measured after return of the vessel diameter to baseline and reported as the greatest absolute increase in EDD. Blood pressure was measured continuously in the study arm by using photoplethysmography (Finapres). Blood flow was calculated as the product of the Doppler time-velocity integral, heart rate, and brachial artery diameter measured by wall tracking at that time.
Biochemical Assays
Lipids, glucose, and creatinine were assayed routinely. tHcy was measured by enzymatic immunoassay (Abbot IMx, Abbot Diagnostics). Plasma malondialdehyde (MDA) and 5-MTHF were measured by high-performance liquid chromatography. 20, 21 Plasma total antioxidant capacity (TAOC) was measured by using a commercially available kit (Randox Laboratories) according to the method of Miller et al. 22 Vitamin B 12 and folate were measured by competitive protein binding assays on an Elecys 2010 analyzer (Roche Diagnostics).
Effect of 5-MTHF, Folic Acid, and BH 4 on Intracellular Superoxide In Vitro
Experiments were performed on cultured porcine endothelial cells to assess the effects of 5-MTHF, folic acid, and tetrahydrobiopterin (BH 4 ) on intracellular superoxide in cells exposed to homocysteine. Free reduced L-homocysteine was prepared from L-homocysteine thiolactone, as described previously. 23 PAE cells were isolated and cultured as previously described, 24 and all experiments were carried out on first-passage cells. PAE cells were incubated at 37°C for 24 hours with buffer or homocysteine alone (1 mmol/L) or were coincubated with homocysteine (1 mmol/L) and 5-MTHF, folic acid, or BH 4 (all at 0.5 mmol/L). Intracellular PAE cell superoxide levels were then measured as previously described. 25 Briefly, cells were washed with sterile saline (0.9% [wt/vol]) before being trypsin (0.05% [wt/vol])-digested and isolated. The resulting cell pellet was resuspended in HEPES-buffered physiological saline, and the cell number measured with a Coulter Counter. Cells were added to an aliquot of buffer, to which lucigenin was added to a final concentration of 500 mol/L. Cells were then placed into the warmed chamber of a luminometer with output measured in millivolts. Intracellular superoxide was measured after the addition of a lysing agent (Triton X-100, 1% [vol/vol]), calculated from the integral for the response, and normalized for cell number.
Withdrawals, Medication Changes, and Compliance
Two subjects were withdrawn from the folic acid study: 1 with a nonfatal myocardial infarction and 1 with atrial fibrillation. During the study, all efforts were made to hold medication constant, but clinical considerations forced changes in 6 patients. Treatment with folic acid was well tolerated, and no side effects were reported. Compliance assessed by a tablet count was 96%.
Statistical Analysis
The main statistical analyses of the folic acid study results were based on 50 subjects after removal of the 2 withdrawals. Prefolate to postfolate changes in biochemical and vascular measurements were compared with corresponding preplacebo to postplacebo changes by using the Hills-Armitage method. 26 The relationships between changes in FMD, homocysteine, and other parameters on folate administration were characterized by the Spearman rank correlation, with 95% CIs calculated by the tanh Ϫ1 method. In the intra-arterial study, paired t tests were used. The main outcome variables of FMD, folate, and homocysteine were little changed after removal of the 6 subjects in whom medication changes took place.
For the in vitro experiments, data are expressed as meanϮSEM (nϭ10) and compared by ANOVA, followed by an appropriate multiple range test. All differences were considered significant at PϽ0.05.
Results
Baseline Characteristics
The folic acid study group consisted of 52 patients aged 57Ϯ8 years (males 57Ϯ8 years, females 58Ϯ8 years). The 5-MTHF study group consisted of 10 similar subjects, aged 55Ϯ9 years (all male). Baseline characteristics were similar in the 2 populations (Table 1) .
Folic Acid Study
Effects on Biochemical Parameters
Biochemical parameters are shown in Table 2 . MDA and plasma TAOC were not significantly altered by folic acid. Vitamin B 12 , lipids, glucose, and creatinine were unchanged by folic acid compared with placebo.
Effects on Flow-Mediated Dilatation and Vascular Measurements
Vascular data involving folic acid treatment are shown in Table 3 . The coefficient of variation for the measurement of FMD in our laboratory was 5.6%. FMD was impaired in the folic acid group at baseline compared with published normal values (50Ϯ33 m and 1.2Ϯ0.97% baseline EDD). 27 FMD significantly improved after folic acid compared with placebo (110Ϯ43 versus 47Ϯ35 m, respectively; PϽ0.001; Figure  1) , and in addition, the time course of vessel diameter change after cuff release was significantly altered (Figure 2 ). Heart rate, blood pressure, baseline brachial artery EDD, peak hyperemic flow, and NTG response did not differ significantly after folic acid. (Table 4) . FMD was impaired in the 10 subjects at baseline compared with published normal values (FMD 43Ϯ15 m, 0.96Ϯ0.34% baseline EDD). 27 5-MTHF acutely improved FMD compared with control (80Ϯ20 versus 43Ϯ15 m, respectively; PϭϽ0.001), an effect that was completely suppressed by coinfusion with L-NMMA (Figure 3 ). Heart rate, blood pressure, baseline brachial artery EDD, peak hyperemic flow, and NTG response did not differ significantly during 5-MTHF infusion compared with control. 
Intra-Arterial 5-MTHF Study
Effects on Biochemical Parameters
In Vitro
Correlates of Improved FMD
Although homocysteine was significantly decreased by folic acid, a positive correlation between improvement in FMD and reduction in plasma homocysteine was not found. To the contrary, there was a trend toward a negative correlation (r s ϭϪ0. 21 
Discussion
The present study demonstrated a significant improvement in endothelial function after 6 weeks of treatment with folic acid (5 mg daily) in subjects with significant CAD on standard therapy and with good lipid control (mean cholesterol 4.7 mmol/L). The majority (88%) of patients were taking statins, which have previously been shown to improve endothelial function, 28 indicating additive benefit.
The oral folate study, statistically the most powerful to our knowledge, confirms and extends the findings of recent parallel group studies of folic acid (5 mg daily) alone or in combination with other B group vitamins on endothelial function in CAD. 14, 15 In previous studies, 14, 15 mean baseline tHcy concentration was higher than that in the present study: 13 mol/L 14 and 12.3 mol/L 15 compared with 11.2 mol/L in the present study. Furthermore, improvement in endothelial function in the present study was not confined to those with higher baseline homocysteine concentrations. Indeed, there was a trend toward greater FMD enhancement in patients with tHcy Ͻ9 mol/L (nϭ14) compared with tHcy Ͼ9 mol/L (nϭ36); change in FMD was 73Ϯ43 versus 47Ϯ43 m, respectively (Pϭ0.07). This suggests that the benefit is independent of pretreatment tHcy level.
We found no correlation between tHcy reduction and improvement in endothelial function and, indeed, observed a trend toward the reverse. This contrasts with the findings of a recent study in which a significant positive correlation between tHcy reduction and improvement in endothelial function was reported. 15 It has recently been suggested that improved endothelial function seen with B group vitamins (which included folic acid) in CAD is mediated by a reduction in free (unbound) but not total homocysteine, in accordance with the observation that FMD improvement is correlated with a reduction in free but not total homocysteine. 14 A number of factors would appear to argue against this correlation being a causal relationship. First, all of the observational data linking homocysteine and cardiovascular risk has been based on total, not free, homocysteine. Second, of the free component, only Ϸ1% is in the reduced form (ie, possesses a free sulfhydryl group), which can support autooxidation and therefore superoxide generation, with the remaining component being oxidized. 29, 30 The pathological significance of such low levels of free reduced homocysteine on oxidative burden in the plasma has been questioned recently. 31 The lack of a positive correlation between the enhancement in endothelial function and tHcy reduction suggests that the beneficial effect of folic acid is unlikely to be mediated principally via tHcy lowering. This proposal is supported by the intra-arterial study, which demonstrated acute improvement in endothelial function after 30 minutes of infusion with 5-MTHF independent of a change in tHcy. This effect has not been previously reported in subjects with CAD. The improvement was abolished by coinfusion with the NO synthase inhibitor L-NMMA, indicating that it was mediated by an increase in NO bioavailability.
Generation of reactive oxygen species is proposed to be an important mechanism of homocysteine-induced endothelial injury. 13 This view is supported by methionine loading in normal subjects, which raises tHcy to Ϸ30 to 35 mol/L and which acutely impairs endothelial function. 12 The mechanism is believed to involve oxidant stress 32 and is abrogated by treatment with antioxidant agents. 33, 34 However, it cannot be assumed that moderately elevated homocysteine levels in the general population exert oxidative stress, because methionine loading results in large unphysiological increases in free reduced homocysteine and methionine. 35 Although some observational studies have shown a correlation between tHcy levels and markers of oxidant stress in the general population, 36,37 a causal relationship has not been established. In the present study, although tHcy was significantly reduced by 19%, there was no reduction in MDA or any increase in TAOC, a marker of the antioxidant capacity of plasma. This suggests either that homocysteine does not directly exert oxidative stress in the plasma or that measurement of MDA and TAOC are not sensitive enough indicators. However, MDA and TAOC were selected because methionine loading in normal subjects is associated with an increase in MDA and decrease in TAOC, indicating that under these conditions, they can detect changes in plasma oxidant stress. 38, 39 The in vitro study used concentrations of homocysteine that were far higher than those experienced in vivo (1 mmol/L versus 10 to 15 mol/L, respectively). The high concentration of homocysteine used was similar to previously published reports of in vitro work. Higher pharmacological concentrations are sometimes required in vitro to reproduce the in vivo situation, in part, because the exposure times used are much shorter than those experienced in hyperhomocysteinemia in humans. The main aim of the present study was to establish homocysteine-induced endothelial dysfunction and investigate possible mechanism(s) by which folate may reverse this and not to mimic the in vivo situation exactly. We have recently reported that exposure of cultured endothelial cells to homocysteine (Ն30 mol/L) stimulates intracellular generation of superoxide. 25 The in vitro study confirmed this finding and further revealed that 5-MTHF can reduce levels of intracellular superoxide, suggesting a possible explanation for improvement in FMD observed in the human study. A number of mechanisms may account for this: (1) intracellular homocysteine was decreased, (2) 5-MTHF scavenged superoxide directly, and/or (3) 5-MTHF reduced superoxide production. Given that it takes some weeks before levels of homocysteine fall significantly with folic acid, a reduction in homocysteine after 24 hours seems unlikely, and other direct actions of 5-MTHF more likely explain this observation. In vitro, 5-MTHF has recently been demonstrated to be capable of directly scavenging superoxide, increasing NO production by eNOS, and also reducing superoxide generation by eNOS. 40 The in vitro study also demonstrated that BH 4 is capable of inhibiting the homocysteine-induced increases in endothelial superoxide. BH 4 is an essential cofactor for eNOS, and its depletion results in uncoupling of eNOS activity and a switch from production of NO, from L-arginine, to generation of superoxide. 41 5-MTHF is essential in the redox cycling of the inactive quinonoid BH 2 (qBH 2 ) back to the active form, BH 4 . 42 Furthermore, oral BH 4 supplementation can improve endothelial function in CAD. 43 Thus, the ability of 5-MTHF to regenerate intracellular BH 4 from qBH 2 may, at least in part, explain the improvement in NO bioavailability observed in the human studies.
Implications of the Present Study
The oral folic acid study supports the finding that high-dose supplementation improves endothelial function in patients with CAD. Furthermore, this improvement is observed in subjects already treated with statins and is independent of baseline tHcy or its reduction. In contrast to earlier reports, the present data do not support the view that improvement is mediated by tHcy reduction but point rather to direct actions of folic acid, possibly mediated by reduction in intracellular but not plasma oxidant stress. The dose of folic acid used was pharmacological, with plasma levels far in excess of the normal range, and it cannot be assumed that the effects demonstrated will apply to low-dose folic acid (400 g/d) or improved dietary intake. In conclusion, folic acid is safe and offers a simple, well-tolerated, and inexpensive therapeutic option for improving endothelial function in subjects with ischemic heart disease. 
